Chiron acquires PGNS for $700 million

CHIR said it will acquire PathoGenesis (PGNS), which specializes in infectious diseases, for $38.50 in cash per PGNS share, a total of $700 million. PGNS's TOBI tobramycin solution for inhalation is m...